Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [2][33]. Core Insights - The MSCI China Healthcare Index has increased by 58.6% from early 2025, outperforming the MSCI China Index by 24.2%. However, there has been a recent pullback of 10% in the healthcare sector, presenting a buying opportunity [1]. - The report highlights a recovery in the demand for domestic innovative drug research and development, driven by a resurgence in capital market financing and an increase in overseas clinical trials for authorized innovative drugs [1]. - The CXO industry is expected to see performance recovery in the second half of 2025, aided by the recent interest rate cuts in the U.S. [1]. - The report emphasizes the importance of monitoring the clinical progress of authorized innovative drug pipelines overseas, as this could serve as a catalyst for stock price increases [4]. Summary by Sections Industry Overview - The report discusses the recent clinical data released at the ESMO conference, focusing on several key drugs and their performance in clinical trials, such as SKB264 and ivonescimab, which show promising results in treating specific types of cancer [4]. - It notes that while business development (BD) activities for innovative drugs are ongoing, stock prices have not reflected this positively, primarily due to valuation concerns [4]. Company Ratings and Valuations - The report provides a detailed valuation table for several companies, including: - **Sangamo Therapeutics (1530 HK)**: Market cap of $8.76 billion, target price of $37.58, with a 34% upside potential [2]. - **Gusongtang (2273 HK)**: Market cap of $932.7 million, target price of $48.28, with a 62% upside potential [2]. - **Giant Biologics (2367 HK)**: Market cap of $5.74 billion, target price of $58.35, with a 40% upside potential [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10.87 billion, target price of $74.00, with a 5% upside potential [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $16.80 billion, target price of $9.40, with a 35% upside potential [2]. - **Innovent Biologics (1801 HK)**: Market cap of $18.94 billion, target price of $110.62, with a 29% upside potential [2].

Core Viewpoint - Multiple companies, including China Feihe and Lianyi Rong Technology, conducted share buybacks on October 24, 2025, with China Feihe leading in both the number of shares repurchased and the total amount spent [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 5.885 million shares for a total of 23.6977 million yuan, representing 0.087% of its total share capital [2]. - Lianyi Rong Technology (09959) repurchased 2.4 million shares for 7.3782 million yuan, accounting for 3.516% of its total share capital [2]. - Beike-W (02423) repurchased 1.1784 million shares for 7 million yuan, which is 1.722% of its total share capital [2]. Group 2: Other Notable Buybacks - Yum China (09987) repurchased 17,800 shares for 6.2549 million yuan, representing 2.830% of its total share capital [2]. - Mengniu Dairy (02319) repurchased 400,000 shares for 5.7447 million yuan, which is 0.545% of its total share capital [2]. - Kangsong Pharmaceutical (01681) repurchased 100,000 shares for 1.5180 million yuan, accounting for 8.582% of its total share capital [2].

Core Points - The company Gushengtang has been actively repurchasing its shares, with a total of 496,590 shares bought back since September 10, amounting to HKD 155 million [1] - The stock price has seen a decline of 10.66% during the same period, despite the recent repurchase activity [1] - Year-to-date, Gushengtang has conducted 54 repurchase transactions, totaling 792,050 shares and an expenditure of HKD 249 million [1] Repurchase Details - On October 24, Gushengtang repurchased 140,600 shares at prices ranging from HKD 29.520 to HKD 29.900, with a total repurchase amount of HKD 4.1767 million [1] - The closing price on the same day was HKD 29.740, reflecting a 0.41% increase [1] - The total trading volume for the day was HKD 20.4211 million [1]

Group 1 - The company, Guoshengtang (02273.HK), announced a share buyback on October 24, 2025, spending HKD 4.1767 million to repurchase 140,600 shares at a price range of HKD 29.52 to 29.90 per share [1] - On October 23, 2025, the company also repurchased 199,000 shares for HKD 5.86 million [1]

Core Viewpoint - The company, Guoshengtang (02273), announced a share buyback plan, indicating confidence in its financial position and future prospects [1] Group 1 - The company will spend HKD 4.1767 million to repurchase 140,600 shares [1]

Core Viewpoint - The company, Gushengtang (02273), announced a share buyback plan, indicating a strategic move to enhance shareholder value through the repurchase of its own shares [1] Group 1 - The company will spend HKD 4.1767 million to repurchase 140,600 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年10月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | ...

Major Events - Minglue Technology (02718) plans to offer 7.219 million Class A shares globally from October 23 to October 28, with cornerstone subscriptions amounting to $59 million [1] - Wisco Properties (00230) received a privatization offer from Wisco Hong Kong at a premium of approximately 104.08%, with trading resuming on October 24 [1] - Junyu Foundation (01757) was acquired by China Venture Capital Holdings for 75% of its shares at a discount of about 79.06%, with trading resuming on October 24 [1] - Kangda Foods (00834) was acquired by Gaosi Shi for approximately 54.69% of the company’s shares at a premium of about 16.23%, with trading resuming on October 24 [1] - Hutchison China MediTech (00013) presented data on HMPL-A251 at the AACR-NCI-EORTC International Conference on Molecular Targeted and Cancer Therapeutics [1] - Giant Bio (02367) received a medical device registration certificate for its Type I α1 collagen lyophilized fiber product [1] - Yiming Anke-B (01541) completed the first patient dosing in the Phase IB/II clinical trial of IMM2510 combined with IMM01 [1] - Heng Rui Medicine (01276) received approval to conduct clinical trials for injection of Rikan Trastuzumab [1] - Hansoh Pharmaceutical (03692) had its application for HS-10365 capsule marketing approval accepted by the National Medical Products Administration [1] - Baixin An-B (02185) completed market access and the first commercial surgery for the IBERIS® RDN system in Switzerland [1] - Haotian International Construction Investment (01341) purchased a total of 646 units of Ethereum as of October 23 [1] Share Buybacks/Reductions - Cornerstone Pharmaceuticals-B (02616) saw CEO Yang Jianxin and senior management purchase an additional 1 million shares [2] - Midea Group (00300) repurchased 1.3434 million A shares for approximately 99.998 million yuan on October 23 [2] - China Communications Construction (01800) repurchased 119.45 million A shares for approximately 10.5994 million yuan on October 23 [2] - Mengniu Dairy (02319) repurchased 700,000 shares for approximately 10.0692 million HKD on October 23 [2] - Lianlian Digital (02598) spent about 7.5555 million HKD to repurchase 967,000 shares on October 23 [2] - Lianyi Rong Technology-W (09959) repurchased 2.47 million shares for approximately 7.4137 million HKD on October 23 [2] - Heng Rui Medicine (01276) repurchased 97,500 A shares for approximately 6.2808 million yuan on October 23 [2] - Gushengtang (02273) repurchased 19,860 shares for approximately 5.8634 million HKD on October 23 [2] Operating Performance - Ping An Good Doctor (01833) reported total revenue of approximately 3.725 billion yuan for the first three quarters, a year-on-year increase of 13.6%, and plans to continue expanding AI technology to enhance medical service efficiency and quality [2] - Sands China Ltd. (01928) reported a 7.5% year-on-year increase in net revenue to $1.9 billion for the third quarter [2] - Livzon Pharmaceutical (01513) announced a net profit attributable to shareholders of 1.754 billion yuan for the first three quarters, a year-on-year increase of 4.86% [2] - China Railway Construction (01186) signed new contracts totaling 1.518765 trillion yuan in the first three quarters, a year-on-year increase of 3.08% [2] - Prada (01913) reported net revenue of 4.07 billion euros for the first three quarters, a year-on-year increase of 9% [2] Additional Performance Metrics - Baio Family Interactive (02100) reported 10.2 million active accounts in the third quarter, a year-on-year increase of 37.8% [3] - Anton Oilfield Services (03337) secured new orders worth 1.273 billion yuan in the third quarter [3]

Core Points - The company Gushengtang has been actively repurchasing its shares, with a total of 482,530 shares bought back since September 10, amounting to HKD 151 million [2][3] - The stock price has seen a decline of 11.02% during the repurchase period, with the latest closing price at HKD 29.620, down 1.73% on the day of the latest buyback [2][3] - Year-to-date, Gushengtang has conducted 53 repurchase transactions, totaling 777,990 shares and an expenditure of HKD 245 million [2][3] Repurchase Details - On October 23, Gushengtang repurchased 198,600 shares at a price range of HKD 29.240 to HKD 29.800, with a total expenditure of HKD 5.8634 million [2] - The highest repurchase price during the recent buyback was HKD 30.200 on October 22, while the lowest was HKD 29.240 on October 23 [2] - The company has consistently repurchased shares over the past 30 days, indicating a strong commitment to supporting its stock price [2][3]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report emphasizes the significance of the ESMO conference, highlighting the achievements of Chinese pharmaceutical companies and suggesting to focus on catalysts such as policies, academic conferences, and business development in Q4 2025 [1][4] - The report indicates a potential market rebound due to increasing industry catalysts, including various academic conferences and favorable policies [4] - The report recommends continued attention to companies with promising clinical pipelines and their global commercialization potential [4][5] Valuation Summary - The report provides a detailed valuation overview of various companies, with all covered companies rated as "Buy" except for two rated as "Neutral" and one as "Sell" [3] - Notable target prices and current prices for selected companies include: - AstraZeneca: Target price 93.30, Current price 83.87 [3] - BeiGene: Target price 225.00, Current price 188.20 [3] - Innovent Biologics: Target price 48.00, Current price 36.42 [3] - I-Mab: Target price 105.00, Current price 86.10 [3] - China Biologic Products: Target price 9.10, Current price 7.43 [3] Market Performance - The Hang Seng Index rose by 2.3% and the Hang Seng Healthcare Index increased by 2.0% during the week of October 14-21, 2025, ranking fifth among twelve industry indices [4][7] - Sub-industry performance showed CXO leading with a 4.5% increase, followed by Internet medicine and biopharmaceuticals [4][7] Institutional Holdings - As of October 21, 2025, the proportion of domestic institutional holdings through Hong Kong Stock Connect decreased slightly to 22.1%, while foreign institutional holdings also saw a minor decline to 38.6% [34][38] - The report notes that both domestic and foreign investors are increasing their positions in innovative drug companies with clear pipeline values [4][38] Clinical Developments - The report highlights significant clinical trial results presented at the ESMO conference, including: - CanSino Biologics' promising data on its PD-1/VEGF inhibitor [5][6] - Rongchang Biopharmaceuticals' HER2 ADC showing significant survival benefits [5][6] - Kelun-Biotech's results indicating substantial improvements in progression-free survival [5][6] - The report suggests that these developments enhance the global competitiveness of the covered companies [5][6]